109 related articles for article (PubMed ID: 9878544)
1. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells.
Tsuchida T; Kijima H; Oshika Y; Tokunaga T; Abe Y; Yamazaki H; Tamaoki N; Ueyama Y; Scanlon KJ; Nakamura M
Biochem Biophys Res Commun; 1998 Dec; 253(2):368-73. PubMed ID: 9878544
[TBL] [Abstract][Full Text] [Related]
2. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.
Tsuchida T; Kijima H; Hori S; Oshika Y; Tokunaga T; Kawai K; Yamazaki H; Ueyama Y; Scanlon KJ; Tamaoki N; Nakamura M
Cancer Gene Ther; 2000 Mar; 7(3):373-83. PubMed ID: 10766343
[TBL] [Abstract][Full Text] [Related]
4. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
[TBL] [Abstract][Full Text] [Related]
5. Ribozyme as an approach for growth suppression of human pancreatic cancer.
Kijima H; Scanlon KJ
Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
[TBL] [Abstract][Full Text] [Related]
6. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line.
Tokunaga T; Tsuchida T; Kijima H; Okamoto K; Oshika Y; Sawa N; Ohnishi Y; Yamazaki H; Miura S; Ueyama Y; Nakamura M
Br J Cancer; 2000 Sep; 83(6):833-9. PubMed ID: 10952790
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
[TBL] [Abstract][Full Text] [Related]
8. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
[TBL] [Abstract][Full Text] [Related]
9. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA.
Cai DW; Mukhopadhyay T; Roth JA
Cancer Gene Ther; 1995 Sep; 2(3):199-205. PubMed ID: 8528963
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
11. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N
J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823
[TBL] [Abstract][Full Text] [Related]
12. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
13. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
Liu G; Chen Y; Zhao X; Dong Y; Chen D
Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
15. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
Ohnami S; Matsumoto N; Nakano M; Aoki K; Nagasaki K; Sugimura T; Terada M; Yoshida T
Cancer Res; 1999 Nov; 59(21):5565-71. PubMed ID: 10554036
[TBL] [Abstract][Full Text] [Related]
16. Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas.
Kimura W; Zhao B; Futakawa N; Muto T; Makuuchi M
Hepatogastroenterology; 1999; 46(25):532-9. PubMed ID: 10228857
[TBL] [Abstract][Full Text] [Related]
17. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
Brembeck FH; Schreiber FS; Deramaudt TB; Craig L; Rhoades B; Swain G; Grippo P; Stoffers DA; Silberg DG; Rustgi AK
Cancer Res; 2003 May; 63(9):2005-9. PubMed ID: 12727809
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture.
Giannini CD; Roth WK; Piiper A; Zeuzem S
Nucleic Acids Res; 1999 Jul; 27(13):2737-44. PubMed ID: 10373591
[TBL] [Abstract][Full Text] [Related]
19. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
Zhu ZW; Friess H; Wang L; Bogardus T; Korc M; Kleeff J; Büchler MW
Clin Cancer Res; 2001 Jan; 7(1):105-12. PubMed ID: 11205897
[TBL] [Abstract][Full Text] [Related]
20. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
